Sciele Pharma, Inc. - Written communication by the subject company relating to a third party tender offer (SC14D9C)
03 Septiembre 2008 - 3:49PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE
COMMISSION
Washington,
D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation
Statement Under
Section 14(d)(4) of the Securities Exchange Act of 1934
SCIELE PHARMA,
INC.
(Name of Subject Company)
SCIELE PHARMA,
INC.
(Name of Person(s) Filing
Statement)
Common Stock,
$0.001 par value per share
(Title or Class of
Securities)
808627103
(CUSIP Number of Class of
Securities)
Patrick P.
Fourteau
Chief Executive Officer
Sciele Pharma, Inc.
5 Concourse Parkway, Suite 1800
Atlanta, Georgia 30328
(770) 442 9707
(Name, address and
telephone number of person authorized
to receive notices
and communications on behalf of the person(s) filing statement)
With Copies to:
W. Tinley
Anderson, III, Esq.
Paul, Hastings, Janofsky & Walker LLP
600 Peachtree St., N. E., Suite 2400
Atlanta, GA 30308
(404) 815-2400
x
Check the box if the filing relates solely to
preliminary communications made before the commencement of a tender offer.
This
Schedule 14D-9 contains the following exhibit:
Exhibit A
Exhibit A is a transcript of a conference call held on
September 2, 2008.
1
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sciele Pharma (MM) (NASDAQ:SCRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sciele Pharma (MM) (NASDAQ): 0 recent articles
Más de Sciele Pharma, Inc. Artículos de Noticias